Zacks Investment Research
11 Aug 2026, 14:50 UTC · 10w ago
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?
Impact · against what's priced in
Merck's strong Q2 revenue beat and raised guidance provide positive momentum, though this is partially offset by lowered EPS targets due to acquisition costs. The stability of Keytruda and contributions from new products like Winrevair support the top-line growth narrative.
- MRK+0.40
No priced-in read yet
- In context
Strong Q2 revenue of $16.61 billion and a raised full-year revenue outlook demonstrate growth, though lowered EPS guidance due to the Terns acquisition creates a headwind.
Read from the article alone
